Summary & Overview
HCPCS G9078: Prostate Adenocarcinoma, High-Risk Disease Status
HCPCS Level II code G9078 designates a disease-status classification for prostate adenocarcinoma with higher-risk features (T2 or T3a staging, Gleason score 8–10, or PSA >20) in the absence of progression, recurrence, or metastases. The code is used within a Medicare-approved demonstration project to standardize reporting for a defined high-risk prostate cancer population. Nationally, standardized disease-status codes like G9078 support program evaluation, quality measurement, and targeted care pathways for oncology patients.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of the code’s clinical context, the likely service type and typical sites of service, and an overview of what to expect in payer coverage considerations and benchmarking when such a code is deployed in demonstration or pilot programs. The publication covers coding interpretation, where G9078 fits in oncology service lines, implications for documentation and reporting, and what missing input elements are present — noting when input fields are not available.
This summary provides a national view of the code’s purpose and utility for clinicians, coding professionals, and policy analysts monitoring oncology reporting initiatives and Medicare demonstration projects.
Billing Code Overview
HCPCS Level II code G9078 describes a specific oncology disease-status classification for prostate cancer limited to adenocarcinoma as the predominant cell type. The code applies when disease stage is T2 or T3a, Gleason score is 8–10, or prostate-specific antigen (PSA) at diagnosis is greater than 20, with no evidence of disease progression, recurrence, or metastases. The description notes use in a Medicare-approved demonstration project.
Service Type: Oncology disease-status classification and reporting
Typical Site of Service: Oncology clinic or hospital outpatient setting, including centers participating in Medicare demonstration projects
Clinical & Coding Specifications
Clinical Context
A 68-year-old man with biopsy-proven prostate adenocarcinoma presents for enrollment and follow-up in a Medicare-approved oncology demonstration project. At diagnosis his tumor is clinical stage T2–T3a with a Gleason score of 8–10 and a prostate-specific antigen (PSA) >20 ng/mL. There is no radiographic or clinical evidence of regional recurrence, distant metastasis, or progression after initial staging (no bone scan or cross-sectional imaging findings suggestive of metastases). The multidisciplinary workflow includes urology or medical oncology confirming histology and stage, baseline PSA and imaging, documentation of no evidence of disease progression or recurrence, discussion of protocol eligibility, and periodic surveillance visits where disease status is reassessed and documented.
Typical steps in the clinical workflow:
-
Referral from primary care or urology after elevated PSA or concerning biopsy results.
-
Histopathology confirming adenocarcinoma as predominant cell type and assignment of Gleason score.
-
Clinical staging (digital rectal exam, pelvic MRI or CT) documenting T2 or T3a disease and no nodal or metastatic disease.
-
Baseline PSA measurement >20 ng/mL at diagnosis recorded in the chart.
-
Enrollment into the Medicare demonstration project with documentation that disease status is stable (no progression, recurrence, or metastases).
-
Periodic follow-up visits to update PSA, exam, and imaging as required by the demonstration protocol and to report disease status under the
G9078billing code.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default or no modifier | Use when no specific modifier applies to the service. |
22 | Increased procedural services | Use when work or complexity substantially exceeds the usual for the service and justification is documented.
23 | Unusual anesthesia | Use when general anesthesia is medically necessary for an otherwise non-anesthesia service (rare for this code).
52 | Reduced services | Use when the service is partially reduced or not completed as documented.
53 | Discontinued procedure | Use when the procedure is started but discontinued for patient safety or other documented reasons.
54 | Surgical care only | Use when billing only for the surgical portion; relevant when other providers bill separate postoperative care.
55 | Postoperative management only | Use when billing only for postoperative care related to a surgical procedure.
56 | Preoperative management only | Use when billing only for preoperative evaluation and preparation.
62 | Two surgeons | Use when two surgeons work together as primary surgeons on complex cases.
AS | Ambulatory surgical center facility | Use when service is performed in an ambulatory surgical center setting.
CO | Worker’s compensation claim (state-specific) | Use when the payer is a workers’ compensation program and this modifier is required.
CQ | Services furnished under a Federal tort claim | Use when services are furnished under Federal Tort Claims Act billing rules.
QK | Medical direction of two, three, or four concurrent anesthesia procedures | Use when applicable anesthesia supervision/medical direction documentation exists.
QX | Monitored anesthesia care (MAC) with certified registered nurse anesthetist (CRNA) service | Use when a CRNA performs anesthesia under appropriate supervision.
| Taxonomy Code | Specialty | Notes |
|---|---|---|
208000000X | Urology | Urologists commonly diagnose, stage, and manage localized prostate adenocarcinoma and coordinate demonstration project enrollment. |
207RC0000X | Radiation Oncology | Radiation oncologists manage definitive radiotherapy and participate in staging and surveillance decisions for localized high-risk disease.
208N00000X | Medical Oncology | Medical oncologists manage systemic therapy considerations and trial/demo project inclusion for high-risk prostate cancer.
208D00000X | Pathology | Pathologists confirm adenocarcinoma histology and Gleason grading on biopsy specimens.
207L00000X | Diagnostic Radiology | Radiologists interpret pelvic MRI, CT, or bone scans used for staging and to confirm absence of metastases.
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
C61 | Malignant neoplasm of prostate | Primary diagnosis for patients meeting the G9078 criteria; indicates prostate cancer. |
D07.5 | Carcinoma in situ of prostate | Not typical for this billing descriptor but may appear in differential pathology; relevant when clarifying invasive adenocarcinoma predominance.
N40 | Benign prostatic hyperplasia | Common comorbidity; may influence symptoms and diagnostic workup but does not qualify for G9078.
R97.2 | Elevated prostate specific antigen (PSA) | Documents the laboratory finding (PSA >20 ng/mL at diagnosis) that contributes to staging and risk stratification.
Z85.47 | Personal history of malignant neoplasm of prostate | Used in surveillance contexts after definitive treatment; relevant when documenting recurrence monitoring but not active progression.
Z21 | Asymptomatic human immunodeficiency virus (HIV) infection status | Included as a generic example of asymptomatic status codes used in registries; not required for G9078 but may appear in medical history documentation.
Z51.89 | Encounter for other specified aftercare | Used for follow-up visits and surveillance in demonstration projects when documenting ongoing disease status without active treatment.
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
76872 | Ultrasound, transrectal; with prostate and volume (separate procedure) | Used during diagnostic biopsy or staging to assess prostate size and guide biopsy sampling prior to enrollment in the demonstration project. |
55700 | Biopsy, prostate; needle or punch, single or multiple, any approach | Performed to obtain tissue confirming adenocarcinoma and Gleason score required for G9078 eligibility.
88305 | Level IV surgical pathology, gross and microscopic examination | Used for prostate biopsy specimen histopathology report documenting adenocarcinoma and Gleason grading.
77072 | CT guidance for localization of radiotherapy fields (simulation) | Performed when radiation therapy is planned for localized high-risk prostate cancer and to document staging and treatment planning.
78320 | Bone imaging, whole body, planar (e.g., bone scan) | Used to evaluate for metastatic disease; absence of positive findings supports G9078 use when no metastases are documented.